Related Experiment Video

Updated: May 23, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy

Fabricio de Carvalho1, André L Vettore, Gisele W B Colleoni

  • 1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, UNIFESP/EPM, Rua Botucatu, 04023-900 Vila Clementino, SP, Brazil. fcarvalho@unifesp.br

Clinical & Developmental Immunology
|April 7, 2012
PubMed

Insights

Cancer/Testis Antigens (CTAs) show promise for cancer immunotherapy. In multiple myeloma, MAGE-C1/CT7 expression correlates with disease progression and promotes cancer cell survival, making it a potential therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Cancer/Testis Antigens (CTAs) are tumor antigens with restricted expression in normal tissues but aberrant expression in cancers.
  • CTAs are epigenetically regulated and represent potential targets for tumor-specific immunotherapy due to immune privilege of gonads.
  • Multiple myeloma (MM) is a hematological malignancy where CTA expression is observed.

Purpose of the Study:

  • To investigate the role of Cancer/Testis Antigens (CTAs) in multiple myeloma (MM).
  • To highlight the significance of MAGE-C1/CT7 as a CTA expressed in MM.

Main Methods:

  • Review of literature on CTA expression in cancer, specifically MM.
  • Analysis of MAGE-C1/CT7 expression patterns and potential functions in MM.

Main Results:

  • MAGE-C1/CT7 is specifically expressed in malignant plasma cells in MM.
  • MAGE-C1/CT7 expression is associated with disease progression in MM.
  • Functional studies suggest MAGE-C1/CT7 promotes MM cell survival by inhibiting apoptosis.

Conclusions:

  • MAGE-C1/CT7 is a relevant CTA in multiple myeloma.
  • MAGE-C1/CT7 plays a role in MM cell cycle and survival.
  • MAGE-C1/CT7 represents a potential therapeutic target for MM immunotherapy.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.